Seroprevalence and genital DNA prevalence of HPV types 6, 11, 16 and 18 in a cohort of young Norwegian women: study design and cohort characteristics

Skjeldestad, Finn Egil; Mehta, Vinay; Sings, Heather L.; Øvreness, Torbjørn; Turpin, Jennifer; Su, L. Joseph; Boerckel, Patricia; Roberts, Christine C.; Bryan, Janine T.; Jansen, Kathrin U.; Esser, Mark T.; Liaw, Kai–Li

doi:10.1080/00016340701714703

Cited by 32 publications

(35 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There is recent evidence that ELISA is a lesssensitive method than the bead-based multiplex assay used in our study (Waterboer et al, 2005). In general, we can conclude that the baseline seroprevalence figures for all HPV types in our study were higher than reported previously (Lehtinen et al, 2006;Rama et al, 2006;Jit et al, 2007;Skjeldestad et al, 2008;Wang et al, 2008). When the more stringent (400 MFI) cut-off value for L1 antibodies was used, seroprevalence declined by [15][16][17][18][19][20]in particular,seroprevalence of HPV 16 (20 %) and HPV 18 (8 %) was in line with earlier reports (Viscidi et al, 1997;af Geijersstam et al, 1998;Stone et al, 2002).…”

Section: S Syrjä Nen and Others 1522contrasting

confidence: 55%

“…In addition, abnormal cytology could not be correlated with positive serology (Rama et al, 2006). In the literature, HPV 16 seroprevalence in the healthy female population seems to vary from 3.4 to 44.0 % (af Geijersstam et al, 1998;Stone et al, 2002;Wang et al, 2003;Lehtinen et al, 2006;Villa et al, 2006;Marais et al, 2007;Skjeldestad et al, 2008;Wang et al, 2008). Seroprevalence seems to be more common among cervical intraepithelial neoplasia or sexually transmitted disease (STD) patients, as well as among women with cervical cancer or human immunodeficiency virus infection (Thompson et al, 2004;Viscidi et al, 2005).…”

Section: Introductionmentioning

confidence: 99%

“…However, there is some evidence that transient HPV infections do not always elicit seroconversion and, also, some women with persistent infection fail to seroconvert (Carter et al, 2000). Only about half of all HPV 16 DNA-positive women tested seropositive for the corresponding HPV type using available assays (Kirnbauer et al, 1994;Wideroff et al, 1996;Carter et al, 1996Carter et al, , 2000Viscidi et al, 1997;Ho et al, 2004;Skjeldestad et al, 2008). In addition, abnormal cytology could not be correlated with positive serology (Rama et al, 2006).…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Dynamics of human papillomavirus serology in women followed up for 36 months after pregnancy

Syrjänen

Waterboer

Sarkola

et al. 2009

Journal of General Virology

View full text Add to dashboard Cite

We determined L1 antibodies for human papillomavirus (HPV) types 6, 11, 16, 18 and 45 by multiplex serology in our prospective HPV family study. We report seroprevalence, seroconversion and antibody decay in 290 women (mean age, 25.5 years) sampled before delivery and at 12, 24 and 36 months of follow-up. Multiplex HPV genotyping of the baseline oral and genital scrapings was performed. At baseline, seroprevalence of HPV 6, 11, 16, 18 and 45 was 53.3, 21.5, 34.9, 21.5 and 9.0 %, respectively. Seropositivity for low-risk HPV (LR-HPV) was associated significantly with age at onset of sexual activity (P50.001), number of sexual partners until age 20 (P50.018), lifetime number of sexual partners (P50.0001), history of genital warts (P50.0001) and being seropositive for high-risk (HR) HPV (P50.0001). The same covariates also predicted seropositivity for HR-HPV. During follow-up, 26.7, 13.9, 17.0, 16.8 and 6.6 % of the women seroconverted to L1 antigen of HPV 6, 11, 16, 18 and 45, respectively, between 18.2 and 23.8 months. Independent predictors of seroconversion to LR-HPV were unemployment (P50.019) and absence of anal sex practice (P50.031), and to HR-HPV, absence of smoking history and lifetime number of sexual partners. Decay of HPV 6, 11, 16, 18 and 45 antibodies was observed in 2.3, 4.0, 5.3, 4.5 and 1.5 % of the women, respectively, with decay time varying from 27.2 to 35.8 months. These data imply that (i) a substantial proportion of young women are seropositive for both LR-and HR-HPV types, (ii) they frequently undergo seroconversion within 18-24 months, predicted by common covariates, and (iii) antibody decay over 3 years is rare.

show abstract

Section: S Syrjä Nen and Others 1522contrasting

confidence: 55%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Dynamics of human papillomavirus serology in women followed up for 36 months after pregnancy

Syrjänen

Waterboer

Sarkola

et al. 2009

Journal of General Virology

View full text Add to dashboard Cite

show abstract

“…The vast majority of HPV seroprevalence studies have been carried out in women from high-resource countries (3,6,(8)(9)(10)(11)(12)(13)(14). Few studies have focused on low-resource areas, such as Central and South America (7,(15)(16)(17), Asia (5,18) or Africa (19), where the highest HPV DNA prevalence in the world can be found, notably among middleaged women (20).…”

Section: Introductionmentioning

confidence: 99%

Seroprevalence of Antibodies against Human Papillomavirus (HPV) Types 16 and 18 in Four Continents: the International Agency for Research on Cancer HPV Prevalence Surveys

Vaccarella

Franceschi²,

Clifford³

et al. 2010

Cancer Epidemiology, Biomarkers &Amp; Prevention

View full text Add to dashboard Cite

Background: Few human papillomavirus (HPV) seroprevalence studies have been carried out in women from low-resource countries.Methods: Seroprevalence of antibodies against HPV16 and HPV18 was assessed in 7,074 women ≥15 years of age (median 44 years) from eight world areas. Serum antibodies against HPV16 and HPV18 were tested for using enzyme-linked immunosorbent assay. HPV DNA was assessed using a general primer GP5 +/6+-mediated PCR.Results: HPV16 and HPV18 seroprevalence both ranged from <1% (Hanoi, Vietnam) to ≥25% (Nigeria). Of women who were HPV16 or HPV18 DNA-positive, seropositivity for the same type was 39.8% and 23.2%, respectively. Seropositivity for either type was directly associated with markers of sexual behavior. HPV16 and/or 18 (HPV16/18)-seropositive women had an increased risk of having cytologic abnormalities only if they were also HPV DNA-positive. A high international correlation was found between HPV16/18 seroprevalence and overall HPV DNA prevalence (r = 0.81; P = 0.022). However, HPV16/18 seroprevalence was substantially higher than the corresponding DNA prevalence in all study areas (although to different extents) and, contrary to DNA, tended to increase from young to middle age, and then decline or remain fairly constant. In all study areas, the vast majority of the information on the burden of exposure to HPV16/18 derived from serology.Conclusions: The correlation between HPV DNA and HPV serology was not very good at an individual woman level, but high at a population level.Impact: HPV serology is a poor marker of current infection or related lesions, but it can contribute, together with DNA, in evaluating the variations in the burden of HPV infection worldwide. Cancer Epidemiol Biomarkers

show abstract

“…Prior infection with HPV does not provide women with adequate immunity against subsequent infections. In fact, serum antibody levels after natural HPV infection when detectable are low and 40-50% of women do not develop measurable antibody response after HPV natural infection (Viscidi et al, 2004;Nonnenmacher et al, 1995;Park et al, 1998;Heim et al, 2002;Skjeldestad et al, 2008). Moreover, it has been shown that an infection with a specific genotype does not decrease the probability of being infected by a phylogenetically-related genotype (Thomas et al, 2000).…”

Section: Prevalence Incidence Duration Co-infection and Re-infectionmentioning

confidence: 99%

Epidemiology of Mucosal Human Papillomavirus (HPV) Infections Among Adult and Children

Trottier¹

2012

Human Papillomavirus and Related Diseases - From Bench to Bedside - Research Aspects

View full text Add to dashboard Cite

Seroprevalence and genital DNA prevalence of HPV types 6, 11, 16 and 18 in a cohort of young Norwegian women: study design and cohort characteristics

Cited by 32 publications

References 24 publications

Dynamics of human papillomavirus serology in women followed up for 36 months after pregnancy

Dynamics of human papillomavirus serology in women followed up for 36 months after pregnancy

Seroprevalence of Antibodies against Human Papillomavirus (HPV) Types 16 and 18 in Four Continents: the International Agency for Research on Cancer HPV Prevalence Surveys

Epidemiology of Mucosal Human Papillomavirus (HPV) Infections Among Adult and Children

Contact Info

Product

Resources

About